- Home
- PDEX vs PBYI Comparison
PDEX vs PBYI Comparison
Compare PDEX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDEX
- PBYI
- Stock Information
- Founded
- PDEX 1978
- PBYI 2010
- Country
- PDEX United States
- PBYI United States
- Employees
- PDEX N/A
- PBYI N/A
- Industry
- PDEX Medical/Dental Instruments
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- PDEX Health Care
- PBYI Health Care
- Exchange
- PDEX Nasdaq
- PBYI Nasdaq
- Market Cap
- PDEX 167.6M
- PBYI 167.3M
- IPO Year
- PDEX N/A
- PBYI N/A
- Fundamental
- Price
- PDEX $43.59
- PBYI $3.59
- Analyst Decision
- PDEX Strong Buy
- PBYI Strong Buy
- Analyst Count
- PDEX 1
- PBYI 1
- Target Price
- PDEX $56.00
- PBYI $7.00
- AVG Volume (30 Days)
- PDEX 64.8K
- PBYI 388.3K
- Earning Date
- PDEX 05-01-2025
- PBYI 07-31-2025
- Dividend Yield
- PDEX N/A
- PBYI N/A
- EPS Growth
- PDEX 379.10
- PBYI 143.51
- EPS
- PDEX 2.76
- PBYI 0.77
- Revenue
- PDEX $64,123,999.00
- PBYI $232,709,000.00
- Revenue This Year
- PDEX $26.92
- PBYI N/A
- Revenue Next Year
- PDEX $4.48
- PBYI N/A
- P/E Ratio
- PDEX $15.70
- PBYI $4.67
- Revenue Growth
- PDEX 29.65
- PBYI 2.68
- 52 Week Low
- PDEX $16.84
- PBYI $2.23
- 52 Week High
- PDEX $70.26
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- PDEX 50.59
- PBYI 55.49
- Support Level
- PDEX $40.49
- PBYI $3.26
- Resistance Level
- PDEX $45.86
- PBYI $3.39
- Average True Range (ATR)
- PDEX 2.08
- PBYI 0.14
- MACD
- PDEX 0.63
- PBYI -0.01
- Stochastic Oscillator
- PDEX 60.88
- PBYI 57.84
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.